GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

TMP-301   Click here for help

GtoPdb Ligand ID: 14266

Synonyms: example 17 [WO2015008073] | HTL-14242 | HTL0014242 | HTL14242 | TMP301
PDB Ligand
Compound class: Synthetic organic
Comment: TMP-301 (formerly HTL0014242) is a selective, and orally bioavailable mGluR5 negative allosteric modulator (NAM) [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 0
Rotatable bonds 2
Topological polar surface area 60.87
Molecular weight 310.71
XLogP 0.13
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC(=NC=C1F)C2=CC(=NC=N2)C3=CC(=CC(=C3)C#N)Cl
Isomeric SMILES C1=CC(=NC=C1F)C2=CC(=NC=N2)C3=CC(=CC(=C3)C#N)Cl
InChI InChI=1S/C16H8ClFN4/c17-12-4-10(7-19)3-11(5-12)15-6-16(22-9-21-15)14-2-1-13(18)8-20-14/h1-6,8-9H
InChI Key FQAXDSVNYVVQSE-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
TMP-301 was progressed to clinical trial as a novel agent for the treatment of alcohol and substance use disorders. It was proposed to reduce the risk of relapse. In late October 2025 it was revealed that the developer was TMP-301 pausing the TMP-301 alcohol use disorder program.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06648668 A Study to Investigate the Interaction Between TMP-301 and Cocaine. Phase 1 Interventional Tempero Bio, Inc.
NCT06648655 A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder Phase 2 Interventional Tempero Bio, Inc.
NCT06025396 Multiple Ascending Dose Study of TMP-301 in Healthy Subjects Phase 1 Interventional Tempero Bio, Inc.
NCT03785054 Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242 Phase 1 Interventional Nxera Pharma UK Limited This was the first in humans study for HTL0014242/TMP-301.